Translational Research Cancer Centers Consortium
Daniel Powell, Ph.D.
Carl June ,M.D. Ph.D.
Seven Springs Mountain Resort
Seven Spring, Pennsylvania.
February 15-17, 2017.
At the 17th Annual Meeting of the American Society of Gene & Cell Therapy, Daniel J. Powell Jr., Ph.D., research associate professor, Ovarian Cancer Research Center, Abramson Cancer Center, was presented with The Outstanding New Investigator Award. The Outstanding New Investigator awards are presented to individuals whose early achievements in the field demonstrate remarkable distinction. Dr. Daniel Powell's important contributions to T cell-based cancer therapy include elucidation of the role of CD27 in human T cell memory, development of a novel dual signaling approach to CAR-T cell therapy to limit toxicity, and identification of CD137 as a marker of naturally occurring tumor-reactive T cells. Click here to read more.
T-Cell Therapy was the brainchild of Dr. Carl June, TRCCC Member and Director of Translational Research, University of Pennsylvania Abramson Cancer Center. In this special, the parents of a young girl suffering from acute lymphoblastic leukemia turn to the Children's Hospital of Pennsylvania looking for a Phase I trial to save their daughter's life, as all other treatments had failed. The Phase I trial of Dr. June's T-Cell Therapy was their last chance for a cure and turned out to be just want the Whiteheads' young daughter needed for a new chance at life. Click here to watch the special.
The American Association of Immunologists proudly announced the 2014 recipients of the AAI Awards for outstanding research and career achievements. TRCCC Member, Carl H. June, M.D., professor of pathology and laboratory medicine at the Perelman School of Medicine and director of translational research, Abramson Cancer Center at the University of Pennsylvania, received the 2014 AAI - Steinman Award for Human Immunology Research. This award recognizes an individual who has made significant contributions to the understanding of immune processes underlying human disease pathogenesis, prevention, or therapy. Congratulations Dr. June! To view the entier list of winners, please click here.
The Translational Research Cancer Centers Consortium (TRCCC) was initiated in 1998 to expedite the progress in immunotherapy and other biologic therapies. The organization has successfully brought together leaders in this field to advance science, collaboration and clinical trials to help individuals diagnosed with cancer.
The Translational Research Cancer Centers Consortium (TRCCC) mission is to gain a greater understanding of the interactions between the immune system and cancer in the setting of biologic therapy of cancer.
Gregory Beatty, M.D., Ph.D.